DelveInsight’s, “Uveal Melanoma Pipeline Insight, 2023,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Uveal Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Uveal Melanoma Emerging drugs, the Uveal Melanoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Uveal Melanoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Uveal Melanoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Uveal Melanoma clinical trials studies, Uveal Melanoma NDA approvals (if any), and product development activities comprising the technology, Uveal Melanoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Uveal Melanoma Pipeline Report

 

• DelveInsight’s Uveal Melanoma Pipeline analysis depicts a robust space with 25+ active players working to develop 30+ pipeline treatment therapies.

 

• The leading Uveal Melanoma Companies includes Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, Array BioPharma, Ono Pharmaceutical, AstraZeneca, Roche, IDEAYA Biosciences, Merck & Co, GlaxoSmithKline, Janssen, and others.

 

• Promising Uveal Melanoma Pipeline Therapies includes AEB071, IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab, BVD-523, CVA21, ICON-1, and others.

 

• The Uveal Melanoma companies and academics are working to assess challenges and seek opportunities that could influence Intraocular (Uveal) melanoma R&D. The Uveal Melanoma pipeline therapies under development are focused on novel approaches to treat/improve Intraocular (Uveal) melanoma.

 

Request a sample and discover the recent breakthroughs happening in the Uveal Melanoma Pipeline landscape @ Uveal Melanoma Pipeline Outlook Report

 

Uveal Melanoma Overview

Uveal melanoma is the most common primary intraocular malignancy in adults. Intraocular is a disease in which malignant cells form in the tissues of the eye. Signs of intraocular melanoma include blurred vision or a dark spot on the iris. While development of uveal melanoma is largely considered to be a sporadic event, certain risk factors including light iris color, light skin color, ability to tan and others predispose individuals to Uveal melanoma. Tests that examine the eye are: Ophthalmoscopy, Slip-lamp examination, Gonioscopy and others have been used to help diagnose intraocular melanoma. A biopsy of the tumor is very rarely needed to diagnose intraocular melanoma. The treatment options include: Surgery, Thermotherapy, Radiation therapy, Coagulation.

 

Uveal Melanoma Emerging Drugs Profile

 

• BVD-523: BioMed Valley Discoveries, Inc

BVD-523 (ulixertinib), a novel targeted cytotoxic designed to inhibit ERK, can be used to treat cancers that harbor mutations in the MAPK signaling pathway. BVD-523, either alone or in combination with other drugs, will be a valuable strategy to safely treat cancers that exhibit abnormal MAPK pathway activity. BVD-523 clinical trials are being evaluated in phase II stage of development  for the treatment of Uveal Melanoma.

 

• AU-011: Aura Biosciences, Inc

AU-011 is being studied in phase II stage for the treatment of Uveal melanoma. Administration of AU-011 into the SC space (SCS) has potential benefits, including significantly higher concentration of drug in the tumor, which may improve certain treatment parameters. The drug has been granted Orphan drug designation and Fast track designation by U.S Food and Drug Administration.

 

• PAC-1: Vanquish Oncology

Procaspase Activating Compound-1 (PAC-1) is being evaluated in phase I/II stage for the treatment of Uveal Melanoma. PAC-1 is a apoptotic stimulant and Caspase 3 stimulant that acts as a central trigger point in the apoptotic pathway and is aberrantly elevated in many cancer types and when activated induces cancer cell death.

 

For further information, refer to the detailed Uveal Melanoma Drugs Launch, Uveal Melanoma Developmental Activities, and Uveal Melanoma News, click here for Uveal Melanoma Ongoing Clinical Trial Analysis

 

Uveal Melanoma Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the therapies for Intraocular (Uveal) melanoma. The companies which have their Intraocular (Uveal) melanoma drug candidates in the most advanced stage, i.e. phase II include BioMed Valley Discoveries, Inc,.

 

Uveal Melanoma Pipeline Segmentation

 

Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

• Oral
• Subcutaneous
• Intravenous
• Intramuscular

 

Molecule Type

• Bispecific Antibody
• Peptides 
• Small molecule
• Gene therapy

 

Find out more about the Uveal Melanoma Pipeline Segmentation, Therapeutics Assessment, and Uveal Melanoma Emerging Drugs @ Uveal Melanoma Treatment Landscape

 

Scope of the Uveal Melanoma Pipeline Report

 

• Coverage- Global

 

• Uveal Melanoma Companies- Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, Array BioPharma, Ono Pharmaceutical, AstraZeneca, Roche, IDEAYA Biosciences, Merck & Co, GlaxoSmithKline, Janssen, and others.

 

• Uveal Melanoma Pipeline Therapies- AEB071, IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab, BVD-523, CVA21, ICON-1, and others.

 

• Uveal Melanoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Uveal Melanoma Pipeline Companies and Therapies, click here @ Uveal Melanoma Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Intraocular (Uveal) melanoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Intraocular (Uveal) melanoma – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Intraocular (Uveal) melanoma Collaboration Deals
9. Late Stage Products (Preregistration)
10. Drug Name: Company Name
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. BVD-523: BioMed Valley Discoveries, Inc
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Preclinical Stage Products
19. Drug Name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Intraocular (Uveal) melanoma Key Companies
23. Intraocular (Uveal) melanoma Key Products
24. Intraocular (Uveal) melanoma- Unmet Needs
25. Intraocular (Uveal) melanoma- Market Drivers and Barriers
26. Intraocular (Uveal) melanoma- Future Perspectives and Conclusion
27. Intraocular (Uveal) melanoma Analyst Views
28. Intraocular (Uveal) melanoma Key Companies
29. Appendix

 

Got Queries? Find out the related information on Uveal Melanoma Mergers and acquisitions, Uveal Melanoma Licensing Activities @ Uveal Melanoma Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/